John V Reynolds

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5029876/publications.pdf

Version: 2024-02-01

122 papers	2,768 citations	236612 25 h-index	223531 46 g-index
123 all docs	123 docs citations	123 times ranked	3836 citing authors

#	Article	IF	Citations
1	Investigating the susceptibility of treatment-resistant oesophageal tumours to natural killer cell-mediated responses. Clinical and Experimental Medicine, 2023, 23, 411-425.	1.9	2
2	Lasting Symptoms After Esophageal Resection (LASER). Annals of Surgery, 2022, 275, e392-e400.	2.1	36
3	Acute Kidney Injury After Esophageal Cancer Surgery. Annals of Surgery, 2022, 275, e683-e689.	2.1	9
4	Advances in the curative management of oesophageal cancer. British Journal of Cancer, 2022, 126, 706-717.	2.9	40
5	C-Reactive Protein and C-Reactive Protein-Based Scores to Predict Survival in Esophageal and Junctional Adenocarcinoma: Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2022, 29, 1853-1865.	0.7	8
6	The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition. Frontiers in Immunology, 2022, 13, 823225.	2.2	6
7	PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma. Scientific Reports, 2022, 12, 3259.	1.6	6
8	PD-1 and TIGIT blockade differentially affect tumour cell survival under hypoxia and glucose deprived conditions in oesophageal adenocarcinoma; implications for overcoming resistance to PD-1 blockade in hypoxic tumours. Translational Oncology, 2022, 19, 101381.	1.7	4
9	Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma. Translational Oncology, 2022, 20, 101406.	1.7	5
10	The Omentum in Obesity-Associated Cancer: A Hindrance to Effective Natural Killer Cell Migration towards Tumour Which Can Be Overcome by CX3CR1 Antagonism. Cancers, 2022, 14, 64.	1.7	5
11	Colonic interposition, a contemporary experience: technical aspects and outcomes. Updates in Surgery, 2021, 73, 1849-1855.	0.9	4
12	International trends in oesophageal cancer survival by histological subtype between 1995 and 2014. Gut, 2021, 70, gutjnl-2020-321089.	6.1	29
13	Comparison of Esophagectomy outcomes between a National Center, a National Audit Collaborative, and an International database using the Esophageal Complications Consensus Group (ECCG) standardized definitions. Ecological Management and Restoration, 2021, 34, .	0.2	12
14	Early experience with a nutrition and survivorship clinic in esophageal cancer. Ecological Management and Restoration, 2021, 34, .	0.2	6
15	Modern oncological and operative outcomes in oesophageal cancer: the St. Jamesâ€™s hospital experience. Irish Journal of Medical Science, 2021, 190, 297-305.	0.8	8
16	A Pilot Study of Gut-Brain Signaling After Octreotide Therapy for Unintentional Weight Loss After Esophagectomy. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e204-e216.	1.8	1
17	Early postoperative decrease of albumin is an independent predictor of major complications after oncological esophagectomy: A multicenter study. Journal of Surgical Oncology, 2021, 123, 462-469.	0.8	9
18	Challenges to quality assurance of surgical interventions in clinical oncology trials: A systematic review. European Journal of Surgical Oncology, 2021, 47, 748-756.	0.5	6

#	Article	IF	Citations
19	Prediction of pathological response to neoâ€adjuvant chemoradiotherapy for oesophageal cancer using vibrational spectroscopy. Translational Biophotonics, 2021, 3, e202000014.	1.4	3
20	A study of the immune infiltrate and patient outcomes in esophageal cancer. Carcinogenesis, 2021, 42, 395-404.	1.3	15
21	Physical recovery in the first six months following oesophago-gastric cancer surgery. Identifying rehabilitative needs: a qualitative interview study. Disability and Rehabilitation, 2021, 43, 1396-1403.	0.9	9
22	Radiation and Immunotherapy in Upper Gastrointestinal Cancers: The Current State of Play. International Journal of Molecular Sciences, 2021, 22, 1071.	1.8	8
23	Prospective study of surgical site infections post-open esophageal cancer surgery, and the impact of care bundles. Ecological Management and Restoration, 2021, 34, .	0.2	2
24	Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma. Frontiers in Oncology, 2021, 11, 627270.	1.3	25
25	Management of chyle leaks following esophageal resection: a systematic review. Ecological Management and Restoration, 2021, 34, .	0.2	15
26	Complement in Tumourigenesis and the Response to Cancer Therapy. Cancers, 2021, 13, 1209.	1.7	18
27	The tumour immune microenvironment in oesophageal cancer. British Journal of Cancer, 2021, 125, 479-494.	2.9	17
28	Identifying outcomes reported in exercise interventions in oesophagogastric cancer survivors: a systematic review. BMC Cancer, 2021, 21, 586.	1.1	3
29	Fractalkine Elicits Chemotactic, Phenotypic, and Functional Effects on CX3CR1+CD27â^' NK Cells in Obesity-Associated Cancer. Journal of Immunology, 2021, 207, 1200-1210.	0.4	7
30	Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers. Biomedicines, 2021, 9, 1024.	1.4	9
31	The Prognostic Value of the Lymph Node in Oesophageal Adenocarcinoma; Incorporating Clinicopathological and Immunological Profiling. Cancers, 2021, 13, 4005.	1.7	4
32	Tissue distribution of Î³Î´ T cell subsets in oesophageal adenocarcinoma. Clinical Immunology, 2021, 229, 108797.	1.4	9
33	546 INTENSIVE SURVEILLANCE AFTER CURATIVE INTENT SURGERY FOR ESOPHAGEAL CANCER: INITIAL RESULTS OF THE ENSURE STUDY. Ecological Management and Restoration, 2021, 34, .	0.2	0
34	627 PL11.02 ENSURE: AN INTERNATIONAL MULTICENTRE STUDY EXPLORING WHETHER SURVEILLANCE AFTER ESOPHAGEAL CANCER SURGERY IMPACTS ONCOLOGICAL AND QUALITY OF LIFE OUTCOMES. Ecological Management and Restoration, 2021, 34, .	0.2	0
35	Effect of the Rehabilitation Program, ReStOre, on Serum Biomarkers in a Randomized Control Trial of Esophagogastric Cancer Survivors. Frontiers in Oncology, 2021, 11, 669078.	1.3	5
36	555 VISCERAL OBESITY: PREVALENCE, AND IMPACT ON OPERATIVE AND ONCOLOGIC OUTCOMES IN THE CURATIVE MANAGEMENT OF ESOPHAGEAL CANCER. Ecological Management and Restoration, 2021, 34, .	0.2	0

#	Article	IF	Citations
37	Preoperative high intensity interval training for oncological resections: A systematic review and meta-analysis. Surgical Oncology, 2021, 38, 101620.	0.8	5
38	552 NON-ALCOHOLIC FATTY LIVER DISEASE AND THE HEPATIC RESPONSE TO SURGERY AMONG PATIENTS WITH ESOPHAGEAL ADENOCARCINOMA. Ecological Management and Restoration, 2021, 34, .	0.2	0
39	Chemical imaging and machine learning for subâ€classification of oesophageal tissue histology. Translational Biophotonics, 2021, 3, e202100004.	1.4	1
40	548 COMPARISON OF ESOPHAGECTOMY OUTCOMES BETWEEN A NATIONAL CENTER, A NATIONAL AUDIT COLLABORATIVE, AND AN INTERNATIONAL DATABASE USING ECCG STANDARDIZED DEFINITIONS. Ecological Management and Restoration, 2021, 34, .	0.2	11
41	Opposing Immune-Metabolic Signature in Visceral Versus Subcutaneous Adipose Tissue in Patients with Adenocarcinoma of the Oesophagus and the Oesophagogastric Junction. Metabolites, 2021, 11, 768.	1.3	3
42	ASO Author Reflections: Can CRP and CRP-Based Scores Predict Survival in Operable Adenocarcinomas of the Esophagus and Esophago-Gastric Junction?. Annals of Surgical Oncology, 2021, , 1.	0.7	1
43	ASO Visual Abstract: C-Reactive Protein and C-Reactive Protein-Based Scores to Predict Survival in Esophageal and Junctional Adenocarcinoma: Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2021, , 1.	0.7	0
44	Response to the Comment on â€œAcute Kidney Injury After Esophageal Cancer Surgery: Incidence, Risk Factors, and Impact on Oncologic Outcomesâ€. Annals of Surgery, 2021, 274, e850-e851.	2.1	4
45	P-OGC11â€ƒVitamin B12 supplementation post gastrectomy. A service audit in St. Jamesâ€™s hospital, Dublin. British Journal of Surgery, 2021, 108, .	0.1	0
46	Embolization or disruption of thoracic duct and cisterna chyli leaks post oesophageal cancer surgery should be first line management for ECCG-defined type III chyle fistulae. Irish Journal of Medical Science, 2020, 190, 1111-1116.	0.8	2
47	Incidence and Grading of Complications After Gastrectomy for Cancer Using the GASTRODATA Registry. Annals of Surgery, 2020, 272, 807-813.	2.1	45
48	Linking Circulating Serum Proteins with Clinical Outcomes in Esophageal Adenocarcinomaâ€”An Emerging Role for Chemokines. Cancers, 2020, 12, 3356.	1.7	13
49	Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib. Scientific Reports, 2020, 10, 12105.	1.6	6
50	Barrettâ€™s Registry Collaboration of academic centers in Ireland reveals high progression rate of low-grade dysplasia and low risk from nondysplastic Barrettâ€™s esophagus: report of the RIBBON network. Ecological Management and Restoration, 2020, 33, .	0.2	13
51	Rehabilitation strategies following oesophagogastric and Hepatopancreaticobiliary cancer (ReStOre) Tj ETQq1 1 0.784314 rgBT /Over	1.1	17
52	Signet ring gastric and esophageal adenocarcinomas: characteristics and prognostic implications. Ecological Management and Restoration, 2020, 33, .	0.2	7
53	The Cancer-Immune Set Point in Oesophageal Cancer. Frontiers in Oncology, 2020, 10, 891.	1.3	15
54	The tumour microenvironment of the upper and lower gastrointestinal tract differentially influences dendritic cell maturation. BMC Cancer, 2020, 20, 566.	1.1	9

#	Article	IF	Citations
55	CD1d expression and invariant natural killer T-cell numbers are reduced in patients with upper gastrointestinal cancers and are further impaired by commonly used chemotherapies. Cancer Immunology, Immunotherapy, 2020, 69, 969-982.	2.0	7
56	Physical function in patients with resectable cancer of the pancreas and liverâ€“a systematic review. Journal of Cancer Survivorship, 2020, 14, 527-544.	1.5	3
57	Preoperative exercise to improve fitness in patients undergoing complex surgery for cancer of the lung or oesophagus (PRE-HIIT): protocol for a randomized controlled trial. BMC Cancer, 2020, 20, 321.	1.1	32
58	International consensus on a complications list after gastrectomy for cancer. Gastric Cancer, 2019, 22, 172-189.	2.7	78
59	Silencing microRNA-330-5p increases MMP1 expression and promotes an invasive phenotype in oesophageal adenocarcinoma. BMC Cancer, 2019, 19, 784.	1.1	10
60	Mucosal-Associated Invariant T Cells Display Diminished Effector Capacity in Oesophageal Adenocarcinoma. Frontiers in Immunology, 2019, 10, 1580.	2.2	45
61	Risk factors for loss of bone mineral density after curative esophagectomy. Archives of Osteoporosis, 2019, 14, 6.	1.0	11
62	Differential Expression Profiles of Oxidative Stress Levels, 8-oxo-dG and 4-HNE, in Barrettâ€™s Esophagus Compared to Esophageal Adenocarcinoma. International Journal of Molecular Sciences, 2019, 20, 4449.	1.8	17
63	Pyrazinib (P3), [(E)-2-(2-Pyrazin-2-yl-vinyl)-phenol], a small molecule pyrazine compound enhances radiosensitivity in oesophageal adenocarcinoma. Cancer Letters, 2019, 447, 115-129.	3.2	17
64	Visceral Adipose Tissue Modulates Radiosensitivity in Oesophageal Adenocarcinoma. International Journal of Medical Sciences, 2019, 16, 519-528.	1.1	10
65	Altered T Cell Migratory Capacity in the Progression from Barrett Oesophagus to Oesophageal Adenocarcinoma. Cancer Microenvironment, 2019, 12, 57-66.	3.1	19
66	Attenuation of satiety gut hormones increases appetitive behavior after curative esophagectomy for esophageal cancer. American Journal of Clinical Nutrition, 2019, 109, 335-344.	2.2	9
67	Can the Efficacy of [18F]FDG-PET/CT in Clinical Oncology Be Enhanced by Screening Biomolecular Profiles?. Pharmaceuticals, 2019, 12, 16.	1.7	9
68	Procedural Surgical RCTs in Daily Practice. Annals of Surgery, 2019, 270, 727-734.	2.1	15
69	Benchmarking Complications Associated with Esophagectomy. Annals of Surgery, 2019, 269, 291-298.	2.1	504
70	Patient and family co-developed participant information to improve recruitment rates, retention, and patient understanding in the Rehabilitation Strategies Following Oesophago-gastric and Hepatopancreaticobiliary Cancer (ReStOre II) trial: Protocol for a study within a trial (SWAT). HRB Open Research, 2019, 2, 27.	0.3	2
71	A pilot study of the impact of Vitamin C supplementation with neoadjuvant chemoradiation on regulators of inflammation and carcinogenesis in esophageal cancer patients. Journal of Cancer Research and Therapeutics, 2019, 15, 185.	0.3	11
72	Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma. Cancer Letters, 2018, 418, 230-238.	3.2	26

#	Article	IF	Citations
73	Outcomes for Esophageal Squamous Cell Carcinoma Treated with Curative Intent in a Western Cohort: Should Multimodal Therapy Be the Gold Standard?. World Journal of Surgery, 2018, 42, 1485-1495.	0.8	9
74	The Mitochondrial Genes BAK1, FIS1 and SFN are Linked with Alterations in Mitochondrial Membrane Potential in Barrettâ€™s Esophagus. International Journal of Molecular Sciences, 2018, 19, 3483.	1.8	6
75	Obesity and gastrointestinal cancer: the interrelationship of adipose and tumour microenvironments. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 699-714.	8.2	100
76	The RESTORE Randomized Controlled Trial. Annals of Surgery, 2018, 268, 747-755.	2.1	58
77	Toward a Consensus on Centralization in Surgery. Annals of Surgery, 2018, 268, 712-724.	2.1	187
78	Identifying a Novel Role for Fractalkine (CX3CL1) in Memory CD8+ T Cell Accumulation in the Omentum of Obesity-Associated Cancer Patients. Frontiers in Immunology, 2018, 9, 1867.	2.2	24
79	Physical decline and its implications in the management of oesophageal and gastric cancer: a systematic review. Journal of Cancer Survivorship, 2018, 12, 601-618.	1.5	47
80	pSTAT3 Levels Have Divergent Expression Patterns and Associations with Survival in Squamous Cell Carcinoma and Adenocarcinoma of the Oesophagus. International Journal of Molecular Sciences, 2018, 19, 1720.	1.8	8
81	siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth. Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 569-590.	2.3	17
82	Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma. Oncotarget, 2018, 9, 33634-33647.	0.8	22
83	Home enteral nutrition recipients: patient perspectives on training, complications and satisfaction. Frontline Gastroenterology, 2017, 8, 79-84.	0.9	13
84	HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients. Cancer Immunology, Immunotherapy, 2017, 66, 841-850.	2.0	34
85	Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett's oesophagus by modulating integrinâ€Î±v trafficking. Journal of Cellular and Molecular Medicine, 2017, 21, 3612-3625.	1.6	13
86	Effects of a multimodal rehabilitation programme on inflammation and oxidative stress in oesophageal cancer survivors: the ReStOre feasibility study. Supportive Care in Cancer, 2017, 25, 749-756.	1.0	32
87	Risk Factors for Anastomotic Stricture Postâ€esophagectomy with a Standardized Sutured Anastomosis. World Journal of Surgery, 2017, 41, 487-497.	0.8	42
88	Emerging Concepts Linking Obesity with the Hallmarks of Cancer. Trends in Endocrinology and Metabolism, 2017, 28, 46-62.	3.1	106
89	Multidisciplinary rehabilitation across the esophageal cancer journey. Journal of Thoracic Disease, 2017, 9, E1140-E1142.	0.6	11
90	Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials. Journal of Thoracic Disease, 2017, 9, S697-S704.	0.6	28

#	Article	IF	Citations
91	MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype. Oncotarget, 2017, 8, 11400-11413.	0.8	32
92	Oesophageal cancer: Commonly familial, possibly heritable.. Journal of Clinical Oncology, 2017, 35, 23-23.	0.8	0
93	Pancreatic Aetiology for Massive Upper Gastrointestinal Haemorrhage in Pregnancy. Case Reports in Surgery, 2016, 2016, 1-4.	0.2	5
94	CCR1 antagonism attenuates T cell trafficking to omentum and liver in obesityâ€associated cancer. Immunology and Cell Biology, 2016, 94, 531-537.	1.0	25
95	The microenvironment of visceral adipose tissue and liver alter natural killer cell viability and function. Journal of Leukocyte Biology, 2016, 100, 1435-1442.	1.5	19
96	Parallel Profiles of Inflammatory and Effector Memory T Cells in Visceral Fat and Liver of Obesity-Associated Cancer Patients. Inflammation, 2016, 39, 1729-1736.	1.7	15
97	Metabolic tumor volume provides complementary prognostic information to EUS staging in esophageal and junctional cancer. Ecological Management and Restoration, 2016, 30, 1-8.	0.2	8
98	The characterization of an intestine-like genomic signature maintained during Barrettâ€™s-associated adenocarcinogenesis reveals an NR5A2-mediated promotion of cancer cell survival. Scientific Reports, 2016, 6, 32638.	1.6	13
99	Physiology, pathophysiology and therapeutic implications of enteroendocrine control of food intake. Expert Review of Endocrinology and Metabolism, 2016, 11, 475-499.	1.2	16
100	Can CT-PET and Endoscopic Assessment Post-Neoadjuvant Chemoradiotherapy Predict Residual Disease in Esophageal Cancer?. Annals of Surgery, 2016, 264, 831-838.	2.1	50
101	Obesity-associated cancer: an immunological perspective. Proceedings of the Nutrition Society, 2016, 75, 125-138.	0.4	30
102	Letter to the Co-Editors-in-Chief, Radiotherapy and Oncology. Radiotherapy and Oncology, 2016, 118, 215.	0.3	0
103	Does the modified Glasgow Prognostic Score (mGPS) have a prognostic role in esophageal cancer?. Journal of Surgical Oncology, 2016, 113, 732-737.	0.8	20
104	Impact of the inflammatory microenvironment on T-cell phenotype in the progression from reflux oesophagitis to Barrett oesophagus and oesophageal adenocarcinoma. Cancer Letters, 2016, 370, 117-124.	3.2	48
105	Factors regulating nuclear factor-kappa B activation in esophageal cancer cells: Role of bile acids and acid. Journal of Cancer Research and Therapeutics, 2016, 12, 364.	0.3	10
106	Gut Hormone Suppression Increases Food Intake After Esophagectomy With Gastric Conduit Reconstruction. Annals of Surgery, 2015, 262, 824-830.	2.1	23
107	Diffuse oesophageal leiomyomatosis. ANZ Journal of Surgery, 2015, 85, 685-686.	0.3	2
108	Prospective Study of Malabsorption and Malnutrition After Esophageal and Gastric Cancer Surgery. Annals of Surgery, 2015, 262, 803-808.	2.1	118

#	Article	IF	Citations
109	Docemur Docemus: Peer-Assisted Learning Improves the Knowledge Gain of Tutors in the Highest Quartile of Achievement but Not Those in the Lowest Quartile. Journal of Surgical Education, 2015, 72, 1139-1144.	1.2	6
110	Molecular mechanisms of constitutive and inducible NF-kappaB activation in oesophageal adenocarcinoma. European Journal of Cancer, 2015, 51, 464-472.	1.3	11
111	Golgi phosphoprotein 2 (GOLPH2) is a novel bile acid-responsive modulator of oesophageal cell migration and invasion. British Journal of Cancer, 2015, 113, 1332-1342.	2.9	13
112	Obesity and increased risk of esophageal adenocarcinoma. Expert Review of Endocrinology and Metabolism, 2015, 10, 511-523.	1.2	3
113	MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma. PLoS ONE, 2015, 10, e0134180.	1.1	33
114	Successful surgical management of early esophageal cancer in a patient with cystic fibrosis post-bilateral lung transplantation. BMJ Case Reports, 2015, 2015, bcr2015210342.	0.2	4
115	Altered Mitochondrial Function and Energy Metabolism Is Associated with a Radioresistant Phenotype in Oesophageal Adenocarcinoma. PLoS ONE, 2014, 9, e100738.	1.1	75
116	The role of obesity in gastrointestinal cancer: evidence and opinion. Therapeutic Advances in Gastroenterology, 2014, 7, 38-50.	1.4	38
117	Defining esophageal landmarks, gastroesophageal reflux disease, and Barrett's esophagus. Annals of the New York Academy of Sciences, 2013, 1300, 278-295.	1.8	17
118	Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma. Annals of the New York Academy of Sciences, 2013, 1300, 187-199.	1.8	25
119	Malignant Gastrocolic Fistula as a Late Complication of Radiation Therapy. Journal of Gastrointestinal Cancer, 2012, 43, 269-272.	0.6	0
120	Challenges in the Treatment of Gastroesophageal Cancer: Reply. World Journal of Surgery, 2011, 35, 1411.	0.8	0
121	Differential Pathologic Variables and Outcomes across the Spectrum of Adenocarcinoma of the Esophagogastric Junction. World Journal of Surgery, 2010, 34, 2821-2829.	0.8	28
122	Multimodality Therapy for Adenocarcinoma of the Esophagus, Gastric Cardia, and Upper Gastric Third. Recent Results in Cancer Research, 2009, 182, 155-166.	1.8	2